New drug combo for tough lung cancer shows promise, but study ends early
NCT ID NCT05636267
First seen Mar 11, 2026 · Last updated May 24, 2026 · Updated 11 times
Summary
This study tested two experimental drugs, AK119 and AK112, with or without chemotherapy, in people with a specific type of advanced lung cancer (EGFR-mutant non-squamous non-small cell lung cancer) that had stopped responding to standard targeted therapy. The goal was to see if the combination was safe and could shrink tumors. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, China
Conditions
Explore the condition pages connected to this study.